title: Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.
abstract: Copper-64 (T(1/2) = 12.7 hours; beta(+), 0.653 MeV [17.8 %]; beta(-), 0.579 MeV [38.4 %]) has decay characteristics that allow for positron emission tomography (PET) imaging and targeted radiotherapy of cancer. The well-established coordination chemistry of copper allows for its reaction with a wide variety of chelator systems that can potentially be linked to peptides and other biologically relevant small molecules, antibodies, proteins, and nanoparticles. The 12.7-hours half-life of 64Cu provides the flexibility to image both smaller molecules and larger, slower clearing proteins and nanoparticles. In a practical sense, the radionuclide or the 64Cu-radiopharmaceuticals can be easily shipped for PET imaging studies at sites remote to the production facility. Due to the versatility of 64Cu, there has been an abundance of novel research in this area over the past 20 years, primarily in the area of PET imaging, but also for the targeted radiotherapy of cancer. The biologic activity of the hypoxia imaging agent, 60/64Cu-ATSM, has been described in great detail in animal models and in clinical PET studies. An investigational new drug application for 64Cu-ATSM was recently approved by the U.S. Food and Drug Administration (FDA) in the United States, paving the way for a multicenter trial to validate the utility of this agent, with the hopeful result being FDA approval for routine clinical use. This article discusses state-of-the-art cancer imaging with 64Cu radiopharmaceuticals, including 64Cu-ATSM for imaging hypoxia, 64Cu-labeled peptides for tumor-receptor targeting, (64)Cu-labeled monoclonal antibodies for targeting tumor antigens, and 64Cu-labeled nanoparticles for cancer targeting. The emphasis of this article will be on the new scientific discoveries involving (64)Cu radiopharmaceuticals, as well as the translation of these into human studies.
authors.affiliation: Mallinckrodt Institute of Radiology, Washington University School of Medicine, Campus Box 8225, St. Louis, MO 63110, USA. andersoncj@mir.wustl.edu
authors.forename: Carolyn J
authors.initials: CJ
authors.lastname: Anderson
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ferdani
mesh_terms: D000818:Animals; D003301:Copper Radioisotopes / Q000737:chemistry; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals / Q000737:chemistry
chemical_list: D003301:Copper Radioisotopes; D019275:Radiopharmaceuticals
references.citation: Cancer Res. 1996 Oct 1;56(19):4509-15
references.pmid: 8813149
references.citation: Biomacromolecules. 2008 Jul;9(7):1997-2006
references.pmid: 18510359
references.citation: Ann Biomed Eng. 2006 Jan;34(1):15-22
references.pmid: 16528617
references.citation: Bioorg Med Chem. 2009 Jan 15;17(2):548-52
references.pmid: 19101152
references.citation: Cancer Res. 1999 Dec 1;59(23):5863-70
references.pmid: 10606224
references.citation: Biomacromolecules. 2007 Oct;8(10):3126-34
references.pmid: 17880180
references.citation: Chemistry. 2008;14(19):5890-907
references.pmid: 18494010
references.citation: Neoplasia. 2005 Mar;7(3):271-9
references.pmid: 15799827
references.citation: Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):850-8
references.pmid: 17262214
references.citation: Cancer Treat Rev. 2004 Feb;30(1):1-17
references.pmid: 14766123
references.citation: Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50
references.pmid: 12692685
references.citation: Dalton Trans. 2007 Jun 7;(21):2150-62
references.pmid: 17514336
references.citation: J Nucl Med. 2008 Feb;49(2):201-5
references.pmid: 18199612
references.citation: Q J Nucl Med Mol Imaging. 2008 Sep;52(3):267-77
references.pmid: 18475250
references.citation: Biomacromolecules. 2005 Sep-Oct;6(5):2541-54
references.pmid: 16153091
references.citation: Nat Protoc. 2006;1(6):3062-8
references.pmid: 17406569
references.citation: Eur J Nucl Med. 1997 Apr;24(4):368-71
references.pmid: 9096086
references.citation: J Nucl Med. 2005 Oct;46(10):1707-18
references.pmid: 16204722
references.citation: J Nucl Med. 2008 Nov;49(11):1819-27
references.pmid: 18927338
references.citation: Nucl Med Biol. 2008 Aug;35(6):713-20
references.pmid: 18678357
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1206-11
references.pmid: 11158618
references.citation: Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
references.pmid: 17056720
references.citation: J Nucl Med. 2007 Feb;48(2):311-8
references.pmid: 17268030
references.citation: Bioconjug Chem. 2004 Jan-Feb;15(1):41-9
references.pmid: 14733582
references.citation: J Nucl Med. 1995 Oct;36(10):1818-24
references.pmid: 7562049
references.citation: Life Sci. 1982 Sep 13;31(11):1133-40
references.pmid: 6128648
references.citation: J Nucl Med. 1995 Dec;36(12):2315-25
references.pmid: 8523125
references.citation: Ann Nucl Med. 2000 Oct;14(5):323-8
references.pmid: 11108159
references.citation: J Nucl Med. 1992 May;33(5):652-8
references.pmid: 1349039
references.citation: J Am Chem Soc. 2006 Aug 30;128(34):11199-205
references.pmid: 16925438
references.citation: Appl Radiat Isot. 2007 Oct;65(10):1115-20
references.pmid: 17669663
references.citation: Cancer Res. 1998 Feb 1;58(3):437-41
references.pmid: 9458086
references.citation: Br J Cancer. 2004 Feb 9;90(3):561-5
references.pmid: 14760364
references.citation: J Nucl Med. 2004 Oct;45(10):1776-83
references.pmid: 15471848
references.citation: Nucl Med Commun. 1998 Mar;19(3):283-8
references.pmid: 9625504
references.citation: Clin Cancer Res. 1997 Dec;3(12 Pt 2):2703-7
references.pmid: 10068277
references.citation: Nucl Med Biol. 2003 Jul;30(5):535-9
references.pmid: 12831992
references.citation: J Nucl Med. 2008 Jul;49(7):1177-82
references.pmid: 18552145
references.citation: J Nucl Med. 2007 Jul;48(7):1162-71
references.pmid: 17574975
references.citation: Bioconjug Chem. 2009 Apr;20(4):750-9
references.pmid: 19320477
references.citation: Chemistry. 2003 Jan 3;9(1):233-48
references.pmid: 12506380
references.citation: Nat Nanotechnol. 2007 Jan;2(1):47-52
references.pmid: 18654207
references.citation: Bioconjug Chem. 2000 Jul-Aug;11(4):527-32
references.pmid: 10898574
references.citation: Cancer Res. 2002 Nov 1;62(21):6146-51
references.pmid: 12414640
references.citation: Technol Cancer Res Treat. 2004 Feb;3(1):33-40
references.pmid: 14750891
references.citation: Bioconjug Chem. 2003 Mar-Apr;14(2):388-94
references.pmid: 12643749
references.citation: Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9
references.pmid: 15380745
references.citation: Int J Radiat Biol. 2006 Oct;82(10):699-757
references.pmid: 17118889
references.citation: Biomacromolecules. 2008 Apr;9(4):1329-39
references.pmid: 18338840
references.citation: Nucl Med Biol. 1999 May;26(4):351-8
references.pmid: 10382836
references.citation: J Med Chem. 2001 Aug 2;44(16):2636-60
references.pmid: 11472217
references.citation: Int J Cancer. 2000 Aug 20;90(4):186-98
references.pmid: 10993959
references.citation: J Nucl Med. 1997 Jul;38(7):1155-60
references.pmid: 9225812
references.citation: Nat Rev Cancer. 2002 Feb;2(2):91-100
references.pmid: 12635172
references.citation: Exp Neurol. 2005 Dec;196(2):381-9
references.pmid: 16197944
references.citation: Int J Biochem Cell Biol. 1997 May;29(5):721-5
references.pmid: 9251239
references.citation: Neurosurgery. 2001 Aug;49(2):380-9; discussion 390
references.pmid: 11504114
references.citation: ACS Nano. 2008 May;2(5):889-96
references.pmid: 19206485
references.citation: J Nucl Med. 2008 Aug;49(8):1371-9
references.pmid: 18632815
references.citation: J Nucl Med. 2007 Nov;48(11):1862-70
references.pmid: 17942800
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8674-82
references.pmid: 15623652
references.citation: Cancer Biother Radiopharm. 2008 Apr;23(2):158-71
references.pmid: 18454685
references.citation: Cancer Biother Radiopharm. 2001 Dec;16(6):483-94
references.pmid: 11789025
references.citation: Science. 2002 Apr 5;296(5565):151-5
references.pmid: 11884718
references.citation: Technol Cancer Res Treat. 2008 Apr;7(2):149-54
references.pmid: 18345704
references.citation: Cancer Res. 2009 Mar 15;69(6):2435-42
references.pmid: 19276378
references.citation: Nucl Med Biol. 2009 Apr;36(3):277-85
references.pmid: 19324273
references.citation: Q J Nucl Med Mol Imaging. 2008 Jun;52(2):101-6
references.pmid: 18043544
references.citation: Curr Opin Biotechnol. 2007 Feb;18(1):26-30
references.pmid: 17254762
references.citation: Nanomedicine (Lond). 2007 Jun;2(3):287-306
references.pmid: 17716175
references.citation: J Med Chem. 1999 Apr 22;42(8):1341-7
references.pmid: 10212119
references.citation: J Nucl Med. 1998 Nov;39(11):1944-51
references.pmid: 9829587
references.citation: Inorg Chem. 1999 Oct 4;38(20):4435-4446
references.pmid: 11671154
references.citation: Macromolecules. 2007;40(9):2971-2973
references.pmid: 18779874
references.citation: Nucl Med Biol. 1997 Jan;24(1):35-43
references.pmid: 9080473
references.citation: Am J Clin Nutr. 1996 May;63(5):797S-811S
references.pmid: 8615367
references.citation: Cancer Res. 1993 Sep 15;53(18):4322-8
references.pmid: 8364927
references.citation: Nucl Med Biol. 1999 Jan;26(1):117-21
references.pmid: 10096511
references.citation: Cell. 1992 Apr 3;69(1):11-25
references.pmid: 1555235
references.citation: FASEB J. 2005 Dec;19(14):2008-10
references.pmid: 16204353
references.citation: Basic Res Cardiol. 2008 Mar;103(2):122-30
references.pmid: 18324368
references.citation: Nucl Med Biol. 1999 Apr;26(3):267-73
references.pmid: 10363797
references.citation: Cancer Res. 1990 Oct 15;50(20):6757-64
references.pmid: 2208139
references.citation: Technol Cancer Res Treat. 2008 Feb;7(1):1-13
references.pmid: 18198919
references.citation: J Clin Invest. 1995 Oct;96(4):1815-22
references.pmid: 7560073
references.citation: J Med Chem. 2005 Apr 21;48(8):2985-92
references.pmid: 15828837
references.citation: J Biol Inorg Chem. 2003 Jan;8(1-2):217-25
references.pmid: 12459917
references.citation: Curr Pharm Biotechnol. 2004 Dec;5(6):495-507
references.pmid: 15579039
references.citation: J Bone Miner Metab. 2007;25(6):337-44
references.pmid: 17968485
references.citation: Q J Nucl Med Mol Imaging. 2008 Jun;52(2):185-92
references.pmid: 18043536
references.citation: J Med Chem. 2002 Jan 17;45(2):469-77
references.pmid: 11784151
references.citation: Cancer Metastasis Rev. 2008 Dec;27(4):631-44
references.pmid: 18523730
references.citation: J Nucl Med. 1999 Jan;40(1):177-83
references.pmid: 9935074
references.citation: Bioconjug Chem. 2002 Jul-Aug;13(4):721-8
references.pmid: 12121126
references.citation: Acta Crystallogr C. 2000 Jan;56 (Pt 1):37-9
references.pmid: 10710660
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5844-9
references.pmid: 18378895
references.citation: J Biol Inorg Chem. 2002 Mar;7(3):249-59
references.pmid: 11935349
references.citation: Clin Physiol Biochem. 1986;4(1):11-9
references.pmid: 3006968
references.citation: J Nucl Med. 2001 Feb;42(2):213-21
references.pmid: 11216519
references.citation: Ultrasound Med Biol. 2007 Jun;33(6):950-8
references.pmid: 17434667
references.citation: Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):764-70
references.pmid: 15785955
references.citation: Drug Discov Today. 2005 Jan 1;10(1):35-43
references.pmid: 15676297
references.citation: Anal Biochem. 1985 Jul;148(1):249-53
references.pmid: 4037304
references.citation: J Med Chem. 2004 Mar 11;47(6):1465-74
references.pmid: 14998334
references.citation: Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8
references.pmid: 12654432